Here are the most and least likely M&A targets in biotech, according to Truist [Seeking Alpha]
Madrigal Pharmaceuticals (MDGL): Reassessing Valuation After Strong 1-Year Share Price Surge [Yahoo! Finance]
Madrigal Pharmaceuticals (NASDAQ:MDGL) was given a new $900.00 price target on by analysts at UBS Group AG.
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)